The Circadian Clock in the Kidney

Lisa R. Stow and Michelle L. Gumz

ABSTRACT

Circadian variations in renal function were first described in the 19th century, and GFR, renal blood flow, urine production, and electrolyte excretion exhibit daily oscillations. These clinical observations are well established, but the underlying mechanisms that govern circadian fluctuations in kidney are not fully understood. Here we provide a brief overview of the machinery governing the circadian clock and examine the clinical and molecular evidence supporting a critical role for circadian rhythm in the kidney. There is a connection between BP oscillation and renal disease that supports the use of chronotherapy in the treatment of hypertension or correction of nondipping BP. Such studies support a developing model of clock-controlled sodium and water transport in renal epithelial cells. Recent advances in identifying novel clock-controlled genes using rodent and cellular models also shed light on the molecular mechanisms by which the circadian clock controls renal function; however, the field is new and much more work remains.

Most physiologic processes, including sleep-wake patterns, heartbeat, and systemic arterial BP, exhibit a circadian pattern of variation. The word circadian is derived from the Latin words circa and dies, meaning about a day. The term circadian is used here to denote biologic processes that occur with a daily, or approximately a 24-hour rhythm. A more stringent definition of circadian is used in studies of biologic rhythms to describe oscillations that occur under constant conditions; a process is considered truly circadian only if the oscillation is maintained in the absence of external zeitgebers, or time cues such as light/dark cycles. It has been over a century since Vogel first reported daily fluctuations in urine volume.1 Healthy individuals excrete more electrolytes and produce more urine during the day than at night, and there are diurnal rhythms for urinary sodium, potassium, and chloride excretion.2 Disruption of these patterns is often associated with hypertension and cardiovascular disease.3,4

The master pacemaker of the circadian clock is located in the suprachiasmatic nucleus (SCN) of the brain. This central clock is entrained by light signals transmitted from the retina through the retinohypothalamic tract. A core group of clock genes functions in a series of transcription-based feedback loops (Figure 1). Transcription factors, Bmal1 and Clock, drive the transcription of the Period (Per1, 2, and 3) and Cryptochrome (Cry1 and 2) genes and nuclear receptor genes, ROR and Rev-erba. The Bmal1/Clock heterodimer regulates gene expression by binding E-box response elements (CANNTG) in the promoter region of target genes. Period and Cryptochrome inhibit Bmal1 and Clock action, thereby repressing their own transcription, whereas ROR and Rev-erba mediate opposing action on Bmal1 expression.5,6 Post-translational modification controls stability and nuclear entry of clock proteins, contributes to the precise timing of the clock mechanism, and is thought to allow crosstalk between physiology and the clock.5,7 In addition to regulating each other to maintain oscillation, the core clock proteins regulate genes that mediate physiologic functions governed by circadian rhythm. These clock-controlled output genes constitute up to 15% of expressed transcripts in some tissues.9

The core clock machinery has been identified in nearly every peripheral tissue. The master clock in the SCN synchronizes the functions of these peripheral clocks through neuronal and humoral signaling.9 As well, body temperature, rest-activity cycles, and feeding cycles contribute to entrainment of the peripheral clocks. Although the relationship between the central and peripheral clocks has been described as co-dependent, the peripheral clocks do not respond identically to cues from the SCN.10–12 Thus, study of the clock in individual tissues is necessary. The role of circadian rhythms has recently been reviewed for the cardiovascular system,13 the vasculature,14,15 metabolic syndrome,16 and the gastrointestinal system.17 Here we examine the clinical and molecular evidence supporting a critical role for the clock in the control of renal function.
Nondipping BP and the Kidney
Cardiovascular events such as stroke and myocardial infarction are known to peak with the morning surge in BP and heart rate. BP increases in the early morning, followed by a plateau during the day, and then dips during sleep.18 Patients who do not exhibit a 10 to 20% decrease in nighttime versus daytime BP are designated “nondippers” and are at increased risk of cardiac death.19 Nondippers exhibit increased left ventricular hypertrophy, carotid artery wall thickness and atherosclerotic plaques, microalbuminuria, cerebrovascular disease, congestive heart failure, vascular dementia, stroke, and myocardial infarction.20 Importantly, nondipping may predict renal damage.21 Several reports link aldosterone signaling to the disruption of circadian BP patterns, suggesting a role for renal function in maintaining normal circadian changes in BP. Patients suffering from aldosteronism exhibit the nondipper pattern,22,23 and treatment with the angiotension II receptor blocker, irbesartan corrects the nondipper pattern in salt-sensitive hypertension.24 The diuretic hydrochlorothiazide restores an appropriate decrease in nocturnal BP in nondipping patients but had no effect in dippers.25 Furthermore, dietary sodium restriction re-establishes the nocturnal dipping pattern.26 Nondipping associates with an increased risk of nephropathy27 and chronic kidney disease.28 Importantly, renal transplantation can rescue the nondipping phenotype,29 although a lack of nocturnal variation can portend poor allograft survival.30 Collectively, these findings suggest a direct link between abnormal circadian patterns in BP and inappropriate sodium transport in the kidney.

Salt handling by the kidney has long been recognized as a critical determinant of BP, and hypertension is rarely observed in the absence of renal dysfunction.31 A decline in renal function directly correlates with a nondipping phenotype. A well-controlled study showed that creatinine clearance declines more rapidly in nondippers compared with dippers, and urinary protein excretion is greater in the nondippers compared with dippers.32 The nondipping phenotype also associates with a faster decline in renal function, and the authors suggested that regulation of nocturnal BP should be an additional goal of anti-hypertensive treatment. Similarly, Agarwal and Light33 determined that a nondipping status was a significant predictor of chronic kidney disease and proteinuria and inferred that correction of dipper status could be an effective therapy for kidney disease. Taken together, these studies showed the important relationship between renal physiology and the circadian pattern of BP.

Chronotherapy in the Treatment of Hypertension
Increasing evidence supports a critical role for the circadian clock in human health. Chronotherapy, the scheduled administration of pharmaceutical agents with respect to an individual’s circadian rhythms, may increase the effectiveness and decrease the side effects of pharmacologic agents.34,35 Chronotherapy has been investigated in the treatment of many nonrenal diseases36–40 and has been proposed for treatment of diabetes,41 cardiac arrhythmias,42 and ischemic heart disease.43

The potential benefits of chronotherapy in the treatment of hypertension include control of BP and normalization of the dipping pattern.44 Cross-sectional and longitudinal studies consistently show that nondipping is a preclinical marker for cardiovascular and renal disease and can be used to predict cardiovascular events.45 Indeed, accruing evidence suggests that nighttime BP is a more important indicator of cardiovascular health than daytime values.46,47 One example comes from a convincing study in which previously untreated hypertensive patients were randomized into groups receiving a single daily dose of ramipril either in the morning or at bedtime.48 BP during sleep was signifi-

Figure 1. Transcriptional mechanism of the circadian clock. Bmal1 and Clock heterodimerize to positively regulate expression of the Period (per) and Cryptochrome (cry) gene families, as well as the retinoic acid orphan receptor (ror) and Nr1d1 (rev-erba) genes. Per/Cry inhibit Bmal1/Clock action to repress their own transcription, whereas ROR and Rev-erba mediate opposing action on bmal1 gene expression. Expression of the Clock protein is constitutive in many tissues. Bmal1/Clock action is mediated through binding of E-box response elements (CANNTG) in the promoters of target genes.

ROLE OF THE CIRCADIAN CLOCK IN THE KIDNEY: CLINICAL EVIDENCE

Several reports link aldosterone signaling to the disruption of circadian BP patterns, suggesting a role for renal function in maintaining normal circadian changes in BP. Patients suffering from aldosteronism exhibit the nondipper pattern,22,23 and treatment with the angiotension II receptor blocker, irbesartan corrects the nondipper pattern in salt-sensitive hypertension.24 The diuretic hydrochlorothiazide restores an appropriate decrease in nocturnal BP in nondipping patients but had no effect in dippers.25 Furthermore, dietary sodium restriction re-establishes the nocturnal dipping pattern.26 Nondipping associates with an increased risk of nephropathy27 and chronic kidney disease.28 Importantly, renal transplantation can rescue the nondipping phenotype,29 although a lack of nocturnal variation can portend poor allograft survival.30 Collectively, these findings suggest a direct link between abnormal circadian patterns in BP and inappropriate sodium transport in the kidney.

Salt handling by the kidney has long been recognized as a critical determinant of BP, and hypertension is rarely observed in the absence of renal dysfunction.31 A decline in renal function directly correlates with a nondipping phenotype. A well-controlled study showed that creatinine clearance declines more rapidly in nondippers compared with dippers, and urinary protein excretion is greater in the nondippers compared with dippers.32 The nondipping phenotype also associates with a faster decline in renal function, and the authors suggested that regulation of nocturnal BP should be an additional goal of anti-hypertensive treatment. Similarly, Agarwal and Light33 determined that a nondipping status was a significant predictor of chronic kidney disease and proteinuria and inferred that correction of dipper status could be an effective therapy for kidney disease. Taken together, these studies showed the important relationship between renal physiology and the circadian pattern of BP.
Recently reduced in bedtime-dosed patients compared with morning-dosed patients. Notably, nighttime dosing also increases the effectiveness of ramipril as BP reduction lasted 24 hours after bedtime dosing compared with 16 hours after morning dosing.

The effect of nighttime administration of anti-hypertensive drugs in nondipping patients has been tested in geographically distinct populations. Anti-hypertensive treatment delivered as an evening dose is highly effective at correcting the nondipping phenotype. Bedtime administration of valsartan, doxazosin (extended release), torasemid, or long-acting nifedipine improves efficacy and reduces side effects of anti-hypertensive treatment. These studies highlight the importance of evaluating the 24-hour BP profile as opposed to single, daytime office measurements. Although these results are promising, larger, more comprehensive trials are needed. A reduction in all-cause mortality would be a convincing outcome. A long-term study following thousands of subjects, the recently completed Monitorización Ambulatoria de la Presión Arterial y Eventos Cardiovasculares—Ambulatory Blood Pressure Monitoring and Cardiovascular Events (MAPEC) trial, was designed to determine whether restoring the dipper pattern using chronotherapy decreases the risk of cardiovascular disease. Providing evidence for the use of chronotherapy in hypertension, the MAPEC results demonstrate that bedtime drug administration, compared to conventional upon-awakening therapy, was more effective at controlling BP and decreasing non-dipping, and resulted in significant reduction of cardiovascular morbidity and mortality.

Circadian Disturbances in Dialysis Patients
Melatonin is an important regulator of the circadian sleep-wake cycle. In healthy individuals, the pineal gland produces melatonin at night; light exposure suppresses melatonin production. The expected nighttime peak in melatonin levels is lost in patients undergoing hemodialysis, and decreased melatonin levels associate with more severe sleep disturbances in these patients. Interestingly, patients receiving nocturnal dialysis experienced the normal nighttime peak in melatonin and reported better sleep quality compared with daytime dialysis patients. A recent study in patients with chronic kidney disease (CKD) found that melatonin amplitude decreases with advancing renal disease, emphasizing the need for further investigation into circadian mechanisms in CKD patients.

Patients undergoing dialysis treatment are more prone to sleep disturbances compared with the general population, resulting in a negative impact on overall health and quality of life. Non-dipping CKD patients seem to have poor sleep quality. Circadian sleep-wake disturbances are common in ESRD patients. Renal disease and dialysis treatment may contribute to the etiology of sleep disturbances in dialysis patients independently of each other. Up to 80% of ESRD patients have reported subjective sleep problems. Daytime sleepiness is increased by dialysis, and this effect is the result of several factors, including elevated body temperature during treatment and the physical and emotional stress caused by the procedure. Likewise, sleep disturbances are a common side effect of medications prescribed to ESRD patients, including β-blockers and benzodiazepines. Several treatments aimed at resynchronizing the sleep-wake rhythm in hemodialysis patients result in some level of sleep improvement. These include a switch to nocturnal hemodialysis, lowering the temperature of the dialyzate, exercise during dialysis, administration of melatonin, or exogenous erythropoietin treatment. Bright light therapy might also benefit hemodialysis patients with circadian sleep disruption.

Circadian Influence on Renal Function
In addition to a role for the kidney in maintaining proper BP rhythms, renal function oscillates in a circadian manner with daily fluctuations in renal blood flow and GFR and the excretion of electrolytes such as sodium and potassium. Likewise, urinary excretion of phosphate, magnesium, and acid oscillates with a circadian pattern. Although these clinical observations have been well established, the underlying molecular mechanisms are unclear.

MOLECULAR EVIDENCE FOR THE ROLE OF A CIRCADIAN CLOCK IN THE KIDNEY
Transcriptional Regulation of Renal Gene Expression by the Circadian Clock
A growing number of genes are regulated by transcriptional mechanisms of the circadian clock. Many clock-controlled genes have been identified in the kidney through either gene expression profiling or candidate gene approaches (Table 1). The term “clock-controlled gene” is used here to describe genes that exhibit rhythmic expression. Most of the genes listed in Table 1 have only recently been linked to the circadian clock, and it remains to be determined whether circadian clock proteins interact with E-box elements in the promoters of these genes.

These genes encode products that range from transcription regulators to cell junction proteins. Although the implications of clock-mediated regulation of these genes are not yet clear, it is interesting that the function of the transcription repressor, Kid-1 (kidney, ischemia, developmentally-regulated gene 1), is linked to regulation of extracellular signal-regulated kinases, providing an intriguing link between a clock-controlled gene and signal transduction in the kidney. Furthermore, the rhythmic expression of E-cadherin and claudin-4 seemed to parallel the circadian changes observed in sodium excretion.

The circadian clock gene Period 1 (Per1) was identified as a novel aldosterone target in a murine inner medullary collecting duct cell line and was the most highly induced transcript in the entire study. Per1 contributes to the basal and aldosterone-dependent transcription of Scnn1a, which encodes the rate-limiting subunit of the epithelial sodium channel. Scnn1a expression is reduced in the renal medulla of Per1 null mice.
null mice excrete more urinary sodium than wild-type mice, although the mechanism of this effect is unknown. The apparent circadian expression of Scnn1a is also altered in mice lacking all three Period genes compared with wild-type mice. Given the critical role of the rate-limiting subunit of the epithelial sodium channel in sodium transport and BP control, these results implicate the clock in the mechanism underlying the known daily fluctuations in sodium excretion and BP.

Many renal transport genes have been identified as clock-controlled genes (Table 2). NHE3 was the first transporter in the kidney to be identified as a target of the clock transcription mechanism. mRNA encoding NHE3 is expressed in a circadian manner in wild-type rodents, but rhythmic expression is blunted in Cry1/Cry2-null mice. A specific E-box response element is required for Bmal1/Clock-mediated transactivation of NHE3 promoter activity. Consistent with this observation is a recent report describing the presence of an E-box in the Scnn1a promoter that is bound by Clock and Per1. Together these studies provide direct molecular evidence for regulation of transport gene expression by the circadian clock.

In the first study of its kind, Zuber et al. used microarray analysis to profile the expression of circadian genes in microdissected distal nephron and collecting duct segments over a 24-hour period. Hundreds of putative clock-controlled genes were identified. Circadian expression of selected genes was confirmed in independent samples, and these genes are included in Tables 1 and 2. These novel clock targets encode moieties ranging from known regulators of sodium transport to critical regulators of water balance. Many of the genes listed in Table 2 are expressed in principal cells of the cortical collecting duct, and the products of these genes contribute to sodium and water transport (Figure 2). Further study will likely identify additional clock-controlled genes, providing additional insight into the mechanism by which the circadian clock regulates water and electrolyte transport in the kidney.


table 1. Clock-controlled genes in the kidney
<table>
<thead>
<tr>
<th>Gene</th>
<th>Function</th>
<th>RNA Source</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dec1</td>
<td>bHLH transcription factor</td>
<td>Whole kidney</td>
<td>59</td>
</tr>
<tr>
<td>Dec2</td>
<td>bHLH transcription factor</td>
<td>Whole kidney</td>
<td>59</td>
</tr>
<tr>
<td>Npas2</td>
<td>bHLH transcription factor</td>
<td>Whole kidney</td>
<td>59</td>
</tr>
<tr>
<td>Dhp</td>
<td>Albumin D-site binding protein</td>
<td>Whole kidney</td>
<td>59</td>
</tr>
<tr>
<td>Cldn4</td>
<td>Claudin 4, Tight junction protein</td>
<td>Whole kidney</td>
<td>60</td>
</tr>
<tr>
<td>E-cadherin</td>
<td>Adherens junctions</td>
<td>Whole kidney</td>
<td>60</td>
</tr>
<tr>
<td>Kid-1</td>
<td>Zn finger transcription repressor</td>
<td>Whole kidney</td>
<td>63</td>
</tr>
<tr>
<td>Cldn8</td>
<td>Claudin 8, Tight junction protein</td>
<td>DCT, CNT</td>
<td>61</td>
</tr>
<tr>
<td>Mapre2</td>
<td>Microtubule associated protein</td>
<td>DCT, CNT, CCD, whole kidney</td>
<td>61</td>
</tr>
<tr>
<td>PtgE</td>
<td>Prostaglandin E synthase</td>
<td>DCT, CNT</td>
<td>61</td>
</tr>
<tr>
<td>TfrC</td>
<td>Transferrin receptor</td>
<td>DCT, CNT, CCD, whole kidney</td>
<td>61</td>
</tr>
</tbody>
</table>

bHLH, basic helix-loop-helix; DCT, distal convoluted tubule; CNT, connecting tubule; CCD, cortical collecting duct.

Table 2. Clock-controlled transport genes in the kidney
<table>
<thead>
<tr>
<th>Gene</th>
<th>Function</th>
<th>RNA Source</th>
<th>Reference</th>
</tr>
</thead>
<tbody>
<tr>
<td>Slc9a3 (NHE3)</td>
<td>Sodium/hydrogen exchange</td>
<td>Whole kidney</td>
<td>66</td>
</tr>
<tr>
<td>Gils</td>
<td>Leucine zipper protein/regulation of sodium transport</td>
<td>DCT, CNT, CCD, Whole kidney</td>
<td>61</td>
</tr>
<tr>
<td>Usp2</td>
<td>Ubiquitin specific protease/regulation of sodium transport</td>
<td>DCT, CNT, CCD, Whole kidney</td>
<td>61</td>
</tr>
<tr>
<td>V1AR</td>
<td>Vasopressin receptor/regulation of water balance</td>
<td>DCT, CNT, CCD, Whole kidney</td>
<td>61</td>
</tr>
<tr>
<td>V2R</td>
<td>Vasopressin receptor/regulation of water balance</td>
<td>DCT, CNT, CCD, Whole kidney</td>
<td>61</td>
</tr>
<tr>
<td>Slc6a6</td>
<td>Taurine transporter</td>
<td>CCD</td>
<td>61</td>
</tr>
<tr>
<td>Slc6a9</td>
<td>Glycine transporter</td>
<td>DCT/CNT</td>
<td>61</td>
</tr>
<tr>
<td>Aqp2</td>
<td>Water channel</td>
<td>CCD</td>
<td>61</td>
</tr>
<tr>
<td>Aqp4</td>
<td>Water channel</td>
<td>CCD</td>
<td>61</td>
</tr>
<tr>
<td>Scnn1a (αENaC)</td>
<td>Alpha subunit of epithelial sodium channel</td>
<td>Cortex, outer medulla and inner medulla</td>
<td>65</td>
</tr>
</tbody>
</table>

DCT, distal convoluted tubule; CNT, connecting tubule; CCD, cortical collecting duct.
with circadian clock disruption suggest that the clock is critical for cardiovascular function. Whereas *Clock*-null mice maintain a normal 24-hour rhythm of BP, the average mean arterial pressure and mean systolic BP were significantly lower in these mice compared with wild type. These mice display altered rhythms in urinary sodium excretion and a mild diuresis. When maintained on a standard 12-hour light/dark cycle, *Per2* mutant mice exhibit decreased 24-hour diastolic BP, increased heart rate, and a decreased difference between day and night BP. Under constant darkness, wild-type mice maintained normal 24-hour rhythms in BP, activity, and heart rate, but *Per2* mutant mice experienced a shortened circadian period. Salt-sensitive hypertension was observed in *Cry1/Cry2* knockout mice. Elevated plasma aldosterone levels were observed in these mice, leading the investigators to perform microarray analysis of adrenal glands from *Cry1/Cry2*-null mice compared with wild type. *Hsd3b6*, a dehydrogenase-isomerase in the aldosterone synthesis pathway, was identified as a highly overexpressed gene in null mice. Increased activity of this enzyme was recorded in *Cry1/Cry2* knockout mice and was linked to the observed salt-sensitive hypertension. Importantly, this study identified a putative target for interventional therapy.

**CONCLUSIONS**

Discerning the role of the circadian clock in the kidney has important implications for the design of novel therapies and improvement of existing treatments for renal disease. Numerous trials showed that chronotherapy in the treatment of nondippers is effective in re-
storing the normal 24-hour rhythm of BP in many patients. Improved use of 24-hour ambulatory BP monitoring could increase identification of nondippers that may benefit from nighttime administration of anti-hypertensive medications. Nighttime dialysis may benefit patients experiencing circadian disruption. To identify those patients most likely to benefit from chronotherapeutic intervention, we must gain a more complete understanding of the mechanism by which the circadian clock regulates renal function.

DISCLOSURES

We thank Dr. Charles Wingo for helpful discussions. This work was supported by Grant K01DK085193 (to M.L.G.).

REFERENCES

20. Smolensky MH, Lemmer B, Reinberg AE:
BRIEF REVIEW


